THE PROGNOSTIC VALUE OF THE NEUTROPHIL-TO-LYMPHOCYTE RATIO IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER AND PULMONARY COMORBIDITIES

Authors

  • Oana Tatiana MIRON Clinical Hospital of Pneumology Iasi
  • V. AFRASINEI “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • L. MIRON “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • F.D. PETRARIU “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Abstract

Aim: This study assesses the prognostic role of the neutrophil-to-lymphocyte ratio (NLR) and other clinical parameters in patients with advanced non-small-cell lung cancer (NSCLC) who also suffer from pulmonary comorbidities. Material and methods: This single-center retrospective research was conducted during January 2015 – December 2018 on patients with the above-mentioned diagnosis. The statistical analysis was carried out with SPSS version 25.0 and focused on evaluating the independent effects of NLR and other parameters by means of univariate and  multivariate Cox regression analyses. Results: Regarding progression-free survival (PFS), the results of the multivariate analysis did not indicate NLR as a prognostic factor (HR: 1.34; 95% CI: 0.85-2.11; p=0.2), unlike the ECOG performance status (HR: 1.71; 95% CI: 1.06-2.77; p=0,02). In terms of overall survival (OS), NLR was an independent negative prognostic factor (HR: 1.8; 95% CI: 1.21-2.69; p=0.004), and so was smoking (HR 1.97; 95% CI: 1.23-3.15; p=0.005). Conclusions: While we did not find NLR to be an independent prognostic factor for PFS in patients with NSCLC and pulmonary comorbidities, it proved to be a negative prognostic factor for OS in these cases.

Author Biographies

  • V. AFRASINEI, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Medical Specialties (III)

  • L. MIRON, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Medical Specialties (III)
    Regional Institute of Oncology Iasi

  • F.D. PETRARIU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Department of Preventive Medicine and Interdisciplinarity

References

1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
2. Cetin K, Ettinger DS, Hei Y-J, O’Malley CD. Survival by histologic subtype in stage IV non-small cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program. Clin Epidemiol 2011; 3: 139-148.
3. Afrăsânie VA, Adavidoaiei AM, Zamisnicu IH, et al. A very rare presentation of lung cancer: Metas-tases to the distal phalanx of index-case report. Medicine (Baltimore) 2019; 98(49): e17892.
4. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454(7203): 436-444.
5. Salciccioli JD, Marshall DC, Pimentel MA, et al. The association between the neutrophil-to-lymphocyte ratio and mortality in critical illness: An observational cohort study. Crit Care 2015; 19(1): 13.
6. Shankaran V, Ikeda H, Bruce AT, et al. IFN gamma and lymphocytes prevent primary tumor devel-opment and shape tumour immunogenicity. Nature 2001; 410(6832): 1107-1111.
7. Gu XB, Tian T, Tian XJ, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in non- small cell lung cancer: A meta-analysis. Sci Rep 2015; 5: 12493.
8. Al-Shibli KI, Donnem T, Al-Saad S, et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008; 14: 5220-5227.
9. Templeton AJ, McNamara MG, Seruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014; 106(6): 124.
10. Azab B, Shah N, Radbel J, et al. Pretreatment neutrophil/lymphocyte ratio is superior to plate-let/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Medical Oncol 2013; 30(1): 432.
11. Liu D, Jin J, Zhang L, et al. The neutrophil to lymphocyte ratio may predict benefit from chemotherapy in lung cancer. Cell Physiol Biochem 2018; 46(4): 1595-1605.
12. Guo D, Li M, Chen D, et al. Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. Future Oncol 2019; 15(6): 625-635.
13. Yu Y, Qian L, Cui J. Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: a meta-analysis of 7,219 patients. Mol Clin Oncol 2017; 7(3): 498-506.
14. Scilla KA, Bentzen SM, Lam VK, et al. Neutrophil-lymphocyte ratio is a prognostic marker in patients with locally advanced (stage IIIA and IIIB) non-small cell lung cancer treated with combined modality therapy. Oncologist 2017; 22(6): 737-742.
15. Diem S, Schimd S, Krapf M, et al. Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratiot (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung cancer 2017; 111: 176-181.

Additional Files

Published

2020-06-30

Issue

Vol. 124 No. 2 (2020): The Medical-Surgical Journal

Section

INTERNAL MEDICINE - PEDIATRICS

License

COPYRIGHT 
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.

COPYRIGHT TRANSFER FORM FOR 

REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /

THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI

We, the undersigned authors of the manuscript entitled

_____________________________________________________________________________________

_____________________________________________________________________________________

warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.

  1. we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
  2. the manuscript does not break the intellectual property rights of any other person.
  3. we have read the submitted version of the manuscript and we are fully responsible for the content.

Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):

  1. ______________________________/_________________________
  2. ______________________________/_________________________
  3. ______________________________/_________________________

N.B.  All the authors must sign this form